BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) have been given a consensus rating of “Moderate Buy” by the five ratings firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $25.00.

Several research analysts have recently weighed in on BBOT shares. Wall Street Zen downgraded BridgeBio Oncology Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. HC Wainwright upped their target price on BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Finally, Canaccord Genuity Group started coverage on BridgeBio Oncology Therapeutics in a research note on Monday, May 11th. They set a “buy” rating and a $23.00 target price for the company.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Laurion Capital Management LP increased its stake in BridgeBio Oncology Therapeutics by 40.1% during the 4th quarter. Laurion Capital Management LP now owns 1,464,938 shares of the company’s stock worth $18,341,000 after buying an additional 419,138 shares in the last quarter. Geode Capital Management LLC increased its stake in BridgeBio Oncology Therapeutics by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 561,987 shares of the company’s stock worth $7,039,000 after buying an additional 20,385 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in BridgeBio Oncology Therapeutics during the 4th quarter worth approximately $1,185,000. XTX Topco Ltd increased its stake in BridgeBio Oncology Therapeutics by 22.4% during the 4th quarter. XTX Topco Ltd now owns 28,633 shares of the company’s stock worth $358,000 after buying an additional 5,249 shares in the last quarter. Finally, Quadrature Capital Ltd purchased a new stake in BridgeBio Oncology Therapeutics during the 4th quarter worth approximately $162,000. 54.89% of the stock is owned by institutional investors and hedge funds.

BridgeBio Oncology Therapeutics Price Performance

Shares of NASDAQ BBOT opened at $7.46 on Friday. The business’s fifty day moving average price is $8.53. BridgeBio Oncology Therapeutics has a 1 year low of $7.00 and a 1 year high of $14.87. The stock has a market capitalization of $597.62 million, a P/E ratio of -3.64 and a beta of 0.29.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($526.11) earnings per share (EPS) for the quarter. As a group, equities analysts predict that BridgeBio Oncology Therapeutics will post -2.32 earnings per share for the current fiscal year.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.